Diethyldithiocarbamate induces apoptosis in HHV-8-infected primary effusion lymphoma cells via inhibition of the NF-κB pathway

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1071-1078

  Matsuno, Takashi ^a   Kariya, Ryusho ^a   Yano, Shuichiro ^a   Morino Koga, Saori ^a   Taura, Manabu ^a   Suico, Mary Ann ^a   Shimauchi, Yuichiro ^a   Matsuyama, Shingo ^a   Okamoto, Yuka ^a   Shuto, Tsuyoshi ^a   Kai, Hirofumi ^a   Okada, Seiji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Diethyldithiocarbamate; NF B; Primary effusion lymphoma cells; Proteasome inhibition

Indexed keywords

CASPASE 3; CASPASE INHIBITOR; DIETHYLDITHIOCARBAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASCITES; BODY WEIGHT; CANCER CELL CULTURE; CONTROLLED STUDY; HERPES VIRUS INFECTION; HUMAN HERPESVIRUS 8; IN VITRO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLENOMEGALY; WEIGHT GAIN;

ANIMALS; APOPTOSIS; CASPASE 3; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DITIOCARB; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, PRIMARY EFFUSION; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84858697399     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1313     Document Type: Article

References (36)

1. Chen YB, Rahemtullah A and Hochberg E: Primary effusion lymphoma. Oncologist 12: 569-576, 2007. (Pubitemid 350012120)
2. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J and Knowles DM: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88: 645-656, 1996. (Pubitemid 26240396)
3. Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S and Oksenhendler E: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23: 4372-4380, 2005. (Pubitemid 46207011)
4. An J, Sun Y, Sun R and Rettig MB: Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene 22: 3371-3385, 2003. (Pubitemid 36713734)
5. Guasparri I, Keller SA and Cesarman E: KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 199: 993-1003, 2004. (Pubitemid 38481090)
6. Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C and Collins M: KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 116: 3721-3728, 2003. (Pubitemid 37185301)
7. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A and Chaudhary PM: The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 277: 13745-13751, 2002. (Pubitemid 34967977)
8. Keller SA, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, Schattner EJ and Cesarman E: NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 107: 3295-3302, 2006.
9. Keller SA, Schattner EJ and Cesarman E: Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96: 2537-2542, 2000.
10. Suh JJ, Pettinati HM, Kampman KM and O'Brien CP: The status of disulfiram: a half of a century later. J Clin Psychopharmacol 26: 290-302, 2006. (Pubitemid 43804621)
11. Sunderman FW Sr: The extended therapeutic role of dithiocarb (sodium diethyldithiocarbamate) from nickel poisoning to AIDS. Ann Clin Lab Sci 22: 245-248, 1992.
12. Pang H, Chen D, Cui QC and Dou QP: Sodium diethyldithiocarbamate, an AIDS progression inhibitor and a copper-binding compound, has proteasome-inhibitory and apoptosis-inducing activities in cancer cells. Int J Mol Med 19: 809-816, 2007.
13. Brewer C: Long-term, high-dose disulfiram in the treatment of alcohol abuse. Br J Psychiatry 163: 687-689, 1993.
14. Hersh EM, Brewton G, Abrams D, Bartlett J, Galpin J, Gill P, Gorter R, Gottlieb M, Jonikas JJ, Landesman S, et al: Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA 265: 1538-1544, 1991.
15. Reisinger EC, Kern P, Ernst M, Bock P, Flad HD and Dietrich M: Inhibition of HIV progression by dithiocarb. German DTC Study Group. Lancet 335: 679-682, 1990. (Pubitemid 20089306)
16. Shinobu LA, Jones SG and Jones MM: Mobilization of aged cadmium deposits by dithiocarbamates. Arch Toxicol 54: 235-242, 1983. (Pubitemid 14232313)
17. Cvek B and Dvorak Z: Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals. Curr Pharm Des 13: 3155-3167, 2007. (Pubitemid 350138963)
18. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D and Ganem D: Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 2: 342-346, 1996. (Pubitemid 26080656)
19. Ono A, Hattori S, Kariya R, Iwanaga S, Taura M, Harada H, Suzu S and Okada S: Comparative study of human hematopoietic cell engraftment into BALB/c and C57BL/6 strain of rag-2/jak3 double-deficient mice. J Biomed Biotechnol 2011: 539748,
20. Hersh EM, Funk CY, Petersen EA, Ryschon KL and Mosier DE: Dose response and timing effects in the therapy of the LP-BM5 murine retrovirus-induced lymphoproliferative immunodeficiency disease with diethyldithiocarbamate. Int J Immunopharmacol 15: 137-143, 1993. (Pubitemid 23096238)
21. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS and Tosato G: Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93: 4034-4043, 1999. (Pubitemid 29279245)
22. Kanno S, Matsukawa E, Miura A, Shouji A, Asou K and Ishikawa M: Diethyldithiocarbamate-induced cytotoxicity and apoptosis in leukemia cell lines. Biol Pharm Bull 26: 964-968, 2003. (Pubitemid 41685420)
23. Asou H, Said JW, Yang R, Munker R, Park DJ, Kamada N and Koeffler HP: Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells. Blood 91: 2475-2481, 1998. (Pubitemid 28155523)
24. Takahashi-Makise N, Suzu S, Hiyoshi M, Ohsugi T, Katano H, Umezawa K and Okada S: Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Int J Cancer 125: 1464-1472, 2009.
25. Zhang C, Hazarika P, Ni X, Weidner DA and Duvic M: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 8: 1234-1240, 2002. (Pubitemid 34517663)
26. Porter AG and Janicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999. (Pubitemid 29082297)
27. Sauna ZE, Shukla S and Ambudkar SV: Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol Biosyst 1: 127-134, 2005. (Pubitemid 43362238)
28. Cataldi A, Rapino M, Centurione L, Sabatini N, Grifone G, Garaci F and Rana R: NF-kappaB activation plays an antiapoptotic role in human leukemic K562 cells exposed to ionizing radiation. J Cell Biochem 89: 956-963, 2003. (Pubitemid 36927727)
29. Herrero JA, Mathew P and Paya CV: LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. J Virol 69: 2168-2174, 1995.
30. Spiller SE, Logsdon NJ, Deckard LA and Sontheimer H: Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer 11: 136, 2011.
31. Safa M, Zand H, Mousavizadeh K, Kazemi A, Bakhshayesh M and Hayat P: Elevation of cyclic AMP causes an imbalance between NF-kappaB and p53 in NALM-6 cells treated by doxorubicin. FEBS Lett 584: 3492-3498, 2010.
32. Han SS, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH and Park S: Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 94: 695-707, 2005. (Pubitemid 41420269)
33. Cvek B and Dvorak Z: The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today 13: 716-722, 2008.
34. Kona FR, Buac D and Burger AM: Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin proteasome system in both preclinical and clinical studies. Curr Cancer Drug Targets 11: 338-346, 2011.
35. Kaplan CS, Petersen EA, Yocum D and Hersh EM: A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection. Life Sci 45: iii-ix, 1989.
36. Komanduri KV, Luce JA, McGrath MS, Herndier BG and Ng VL: The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J Acquir Immune Defic Syndr Hum Retrovirol 13: 215-226, 1996.